Drug profile · INN
pemetrexed dipotassium
AXTLE
pemetrexed dipotassium (AXTLE) is a dihydrofolate reductase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — pemetrexed dipotassium
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 3
- Programs
- 1
- Data quality
- 0.84
Quick answer
pemetrexed dipotassium (AXTLE) is a dihydrofolate reductase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is pemetrexed dipotassium?
pemetrexed dipotassium (AXTLE) is a dihydrofolate reductase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for pemetrexed dipotassium?
AXTLE is a marketed brand name for pemetrexed dipotassium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pemetrexed dipotassium?
pemetrexed dipotassium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.